In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Son-Of-Xigris Goes to Biotech--Where it Belongs?

Executive Summary

When Eli Lilly licensed the follow-on drug candidate to sepsis treatment Xigris to Cardiome, it was a tacit acknowledgment that this family of specialist products may be better suited to biotech. Perhaps they should have done the same with Xigris.
Advertisement

Related Content

Sepsis: A Market in Need
Deals Of The Week: GSK/Apeiron, Cephalon/Mepha, Medco/DNA Direct...
GSK Hunts for Novelty By Paying £11m To Apeiron In A Respiratory Deal
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Protein C: Saving Lives, Saving Lilly
Protein C: Saving Lives, Saving Lilly

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel